Group 1 - The CRO sector experienced a slight increase of 0.66% with a total capital inflow of 84.32 million [1] - A total of 27 stocks within the sector saw gains, while 11 stocks experienced declines [1] - The top declining stocks included Yaokang Bio (-3.64%), Zhaoyan New Drug (-2.68%), and Meidi West (-2.04%) [1] Group 2 - Notable stocks with significant capital inflow included Baicheng Pharmaceutical with a price of 48.06 and a rise of 6.05% [1] - Other stocks with positive performance included Heyuan Bio (+4.39%) and Jinkai Biotechnology (+2.76%) [1] - The stock with the highest capital outflow was Yao Stone Technology, which saw a decrease of 8.88% [1]

Core Viewpoint - The company is holding its third extraordinary general meeting of shareholders in 2025 to discuss and vote on the proposed 2025 Restricted Stock Incentive Plan and related management measures, aiming to enhance employee motivation and align interests among shareholders, the company, and core team members [7][8][11]. Group 1: Meeting Procedures - Shareholders and their representatives must sign in at least half an hour before the meeting and present necessary identification documents [2][3]. - The meeting will follow a specific agenda, allowing shareholders to exercise their rights to speak, inquire, and vote [2][3][5]. - Voting will be conducted through both on-site and online methods, with results announced after the meeting [4][5]. Group 2: Proposed Resolutions - The first resolution involves the approval of the 2025 Restricted Stock Incentive Plan draft, which aims to establish a long-term incentive mechanism to enhance employee engagement and align interests [7][8]. - The second resolution pertains to the management measures for implementing the 2025 Restricted Stock Incentive Plan, ensuring its effective execution [9][10]. - The third resolution seeks authorization for the board of directors to handle all matters related to the stock incentive plan, including adjustments and necessary approvals [10][11].

股票简称：和元生物 股票代码：688238 2025 年第三次临时股东会 会议资料 2025 年 7 月 和元生物技术（上海）股份有限公司 2025 年第三次临时股东会会议资料 和元生物技术（上海）股份有限公司 OBiO Technology (Shanghai) Corp., Ltd. 和元生物技术（上海）股份有限公司 2025 年第三次临时股东会会议资料目录 | 2025 年第三次临时股东会会议须知 | 2 | | --- | --- | | 2025 年第三次临时股东会会议议程 | 4 | | 2025 年第三次临时股东会会议议案 | 6 | | 议案一、《关于公司<2025 年限制性股票激励计划（草案）>及其摘要的议案》 | | | | 7 | | 议案二、《关于公司<2025 年限制性股票激励计划实施考核管理办法>的议案》 | | | | 9 | | 议案三、《关于提请股东会授权董事会办理股权激励相关事宜的议案》 | 10 | 1 和元生物技术（上海）股份有限公司 2025 年第三次临时股东会会议资料 和元生物技术（上海）股份有限公司 2025 年第三次临时股东会会议须知 为维护广大投资者的合法权益 ...

一、本次员工持股计划的基本情况 证券代码：688238 证券简称：和元生物 公告编号：2025-051 和元生物技术（上海）股份有限公司 关于第一期员工持股计划 股票出售完毕暨终止的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 和元生物技术（上海）股份有限公司（以下简称"公司"）第一期员工持股 计划（以下简称"本次员工持股计划"）所持有的公司股票已全部出售完毕。根 据《和元生物技术（上海）股份有限公司第一期员工持股计划管理办法》等相关 规定，本次员工持股计划实施完毕并终止，现将相关情况公告如下： 本次员工持股计划实施期间，严格遵守市场交易规则及中国证券监督管理委 员会、上海证券交易所关于信息敏感期不得买卖股票的规定，未发现有利用内幕 信息进行交易的情形。 特此公告。 和元生物技术（上海）股份有限公司董事会 2025 年 7 月 2 日 2 公司于 2024 年 2 月 6 日召开第三届董事会第十二次会议、第三届监事会第 八次会议，并于 2024 年 2 月 28 日召开 2024 年第一次临时股东大会，审议通过 了 ...

Group 1 - The company held its second extraordinary general meeting of shareholders on June 27, 2025, to elect the fourth board of directors, including non-independent and independent directors, along with employee representative directors [1][2] - The newly elected board consists of four non-independent directors and four independent directors, along with one employee representative director, with a term of three years starting from the approval date of the meeting [2][3] Group 2 - The first meeting of the fourth board of directors was held on June 27, 2025, where several key resolutions were passed, including the election of the chairman and the establishment of various specialized committees [2][4] - Mr. Pan Oudong was elected as the chairman of the fourth board, and various committees such as the Strategy and ESG Committee, Audit Committee, Compensation and Assessment Committee, and Nomination Committee were formed with specific members [3][4] Group 3 - The company appointed Mr. Pan Oudong as the general manager and several other individuals as vice general managers and financial officers, with their terms aligned with the board's term [5][6] - The newly appointed senior management team includes individuals with relevant qualifications and experience, ensuring compliance with legal and regulatory requirements [6][9] Group 4 - The company has decided to abolish the supervisory board, transferring its powers to the audit committee of the board, and the relevant rules have been updated accordingly [7] - The previous supervisory board members have completed their terms and will no longer serve in their roles, with acknowledgments for their contributions during their tenure [7][8]

Group 1 - The company is preparing for the election of its fourth board of directors, which will consist of 9 members, including 1 employee representative director [1][2] - The term of the fourth board of directors will last for three years, starting from the date of approval at the company's second extraordinary general meeting in 2025 [2] - The employee representative director elected is Mr. Song Sijie, who has a background in legal affairs and management within the company [2][3] Group 2 - Mr. Song Sijie meets all qualifications to serve as a director according to the Company Law and the company's articles of association, with no disqualifications or legal issues [3]

Core Points - The company has proposed a 2025 Restricted Stock Incentive Plan, which aims to enhance the long-term incentive mechanism and align the interests of shareholders, the company, and core team members [8][9][30] - The plan intends to grant a total of 3,745,400 restricted shares, accounting for approximately 0.58% of the company's total share capital as of the announcement date [2][19] - The initial grant will be distributed among 61 individuals, primarily including directors, senior management, and key technical and business personnel [3][13] Summary by Sections Incentive Plan Overview - The incentive plan is based on various legal frameworks, including the Company Law and Securities Law of the People's Republic of China [1] - The plan will utilize restricted stock as the incentive method, sourced from the company's repurchased A-shares [1][2] Grant Conditions - The initial grant price for the restricted shares is set at 3.09 yuan per share, with adjustments possible based on corporate actions [5][23] - The plan's effective period is from the grant date until all shares are vested or become void, lasting no more than 36 months [6][7] Eligible Participants - The plan targets 61 individuals, representing about 8.82% of the total workforce, excluding independent directors and major shareholders [3][13] - The eligibility criteria for participants include holding a labor or service relationship with the company during the grant and assessment periods [13][14] Performance and Vesting Conditions - Vesting of the restricted shares will occur in two phases, with 50% vesting after 12 months and the remaining 50% after 24 months, contingent on meeting performance targets [21][25] - The performance targets are based on the company's revenue growth rates for the fiscal years 2025 and 2026, with specific thresholds set for vesting [30][31] Management and Oversight - The company's board of directors and the remuneration and assessment committee will oversee the implementation and management of the incentive plan [11][12] - Any changes to the plan must be approved by the shareholders' meeting, ensuring compliance with relevant regulations [12][14] Adjustments and Compliance - The plan includes provisions for adjusting the number of restricted shares in response to corporate actions such as stock splits or dividends [30] - The company commits not to provide financial assistance to participants for purchasing the restricted shares [6][7]

证券代码：688238 证券简称：和元生物 公告编号：2025-045 和元生物技术（上海）股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 1、出席会议的股东和代理人人数 | 77 | | --- | --- | | 普通股股东人数 | 77 | | 2、出席会议的股东所持有的表决权数量 | 175,771,886 | | 普通股股东所持有表决权数量 | 175,771,886 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 27.8866 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 27.8866 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东大会由公司董事会召集，董事长潘讴东先生主持，采用现场表决与 网络投票相结合的方式召开。本次会议的召集、召开及表决方式符合《中华人民 共和国公司法》《上海证券交易所科创板股票上市规则》及《和元生物技术（上 海）股份有限公司章程》 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-047 和元生物技术（上海）股份有限公司 第四届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 和元生物技术（上海）股份有限公司（以下简称"公司"）第四届董事会第 一次会议于 2025 年 6 月 27 日以现场会议方式召开。本次会议经全体董事一致同 意豁免会议提前通知期限。会议应到董事 9 人，实到董事 9 人，公司高级管理人 员列席了本次董事会。 本次会议由全体董事推举潘讴东先生召集和主持，会议的召集和召开符合 《中华人民共和国公司法》（以下简称"《公司法》"）等有关法律法规及《和 元生物技术（上海）股份有限公司章程》（以下简称"《公司章程》"）的规定。 二、董事会会议审议情况 经与会董事审议表决，形成的会议决议如下： (一) 审议通过《关于选举公司第四届董事会董事长的议案》 根据《公司法》《上海证券交易所科创板股票上市规则》（以下简称"《科 创板上市规则》"）、《上海证券交易所科创板上市公司自律监管指引第 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-049 和元生物技术（上海）股份有限公司 2025 年限制性股票激励计划（草案）摘要公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 股权激励方式：第二类限制性股票。 股份来源：和元生物技术（上海）股份有限公司（以下简称"公司"） 向激励对象授予本公司自二级市场回购的 A 股普通股股票作为本激励计划的股 票来源。 股权激励计划拟授出的权益数量及占公司股份总额的比例：公司 2025 年限制性股票激励计划（以下简称"本激励计划"）拟授予激励对象的限制性股 票数量为 3,745,400 股，约占本激励计划草案公告日公司股本总额 64,903.67 万股的 0.58%。其中，首次授予限制性股票 2,996,400 股，约占本激励计划草案 公告日公司股本总额的 0.46%，占本激励计划拟授予限制性股票总数的 80.00%； 预留部分 749,000 股，约占本激励计划草案公告日公司股本总额的 0.12%，预留 部分占本激励计划拟授予限制性股票总数的 ...